Intra-Cellular Therapies, Inc.
(NASDAQ : ITCI)

( )
ITCI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.94%240.321.3%$790.96m
IMMUImmunomedics, Inc. 0.15%85.3011.0%$689.14m
MRNAModerna, Inc. -2.96%65.170.0%$688.38m
GILDGilead Sciences, Inc. -1.33%62.251.0%$574.97m
NVAXNovavax, Inc. 0.86%102.4496.5%$560.41m
ILMNIllumina, Inc. 4.88%286.313.5%$502.92m
REGNRegeneron Pharmaceuticals, Inc. -1.37%557.462.7%$425.08m
BIIBBiogen, Inc. -0.79%270.041.6%$333.15m
VRTXVertex Pharmaceuticals, Inc. -0.26%263.131.9%$328.25m
ALXNAlexion Pharmaceuticals, Inc. -0.37%112.022.0%$278.23m
SRNESorrento Therapeutics, Inc. -4.27%9.191.5%$246.35m
EXASEXACT Sciences Corp. 26.85%94.3120.7%$232.04m
SGENSeattle Genetics, Inc. 0.09%179.436.0%$203.87m
VXRTVaxart, Inc. -4.17%6.890.0%$198.58m
MNTAMomenta Pharmaceuticals, Inc. 0.19%52.393.0%$197.85m

Company Profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.